CD8A and neoplasm: CTNNB1 gain-of-function (GOF) mutations promote MMP9 secretion in the TME of HCC, inhibiting the activity of CD8+ T cells and leading to the immune escape of tumour cells and resistance to anti-PD-1 therapy.